Reviews - 4hix mentioned but not cited (4)
- Passive immunotherapies targeting Aβ and tau in Alzheimer's disease. Plotkin SS, Cashman NR. Neurobiol Dis 144 105010 (2020)
- Conformational selection in amyloid-based immunotherapy: Survey of crystal structures of antibody-amyloid complexes. Ma B, Zhao J, Nussinov R. Biochim Biophys Acta 1860 2672-2681 (2016)
- Alzheimer's disease--a panorama glimpse. Zhao LN, Lu L, Chew LY, Mu Y. Int J Mol Sci 15 12631-12650 (2014)
- Structural biology of cell surface receptors implicated in Alzheimer's disease. Hermans SJ, Nero TL, Morton CJ, Gooi JH, Crespi GAN, Hancock NC, Gao C, Ishii K, Markulić J, Parker MW. Biophys Rev 14 233-255 (2022)
Articles - 4hix mentioned but not cited (5)
Reviews citing this publication (16)
- The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics. Karran E, De Strooper B. Nat Rev Drug Discov 21 306-318 (2022)
- A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease. Karran E, Hardy J. Ann Neurol 76 185-205 (2014)
- Focusing the amyloid cascade hypothesis on N-truncated Abeta peptides as drug targets against Alzheimer's disease. Bayer TA, Wirths O. Acta Neuropathol 127 787-801 (2014)
- Antibody-Based Drugs and Approaches Against Amyloid-β Species for Alzheimer's Disease Immunotherapy. Liu J, Yang B, Ke J, Li W, Suen WC. Drugs Aging 33 685-697 (2016)
- D-amino acid-based peptide inhibitors as early or preventative therapy in Alzheimer disease. Kumar J, Sim V. Prion 8 119-124 (2014)
- Recent advancements toward therapeutic vaccines against Alzheimer's disease. Herline K, Drummond E, Wisniewski T. Expert Rev Vaccines 17 707-721 (2018)
- Anti-Aβ Antibodies and Cerebral Amyloid Angiopathy Complications. Chantran Y, Capron J, Alamowitch S, Aucouturier P. Front Immunol 10 1534 (2019)
- Antibody Engineering for Optimized Immunotherapy in Alzheimer's Disease. Sumner IL, Edwards RA, Asuni AA, Teeling JL. Front Neurosci 12 254 (2018)
- Hypometabolism, Alzheimer's Disease, and Possible Therapeutic Targets: An Overview. Raut S, Bhalerao A, Powers M, Gonzalez M, Mancuso S, Cucullo L. Cells 12 2019 (2023)
- Structure and Function of Alzheimer's Amyloid βeta Proteins from Monomer to Fibrils: A Mini Review. Agrawal N, Skelton AA. Protein J 38 425-434 (2019)
- The Development of Pharmacological Therapies for Alzheimer's Disease. Lin P, Sun J, Cheng Q, Yang Y, Cordato D, Gao J. Neurol Ther 10 609-626 (2021)
- [Alzheimer's disease: New therapeutic strategies]. Villegas S. Med Clin (Barc) 145 76-83 (2015)
- A light at the end of the tunnel - from mutation identification to a potential treatment for Alzheimer's disease. Lannfelt L. Ups J Med Sci 128 (2023)
- Alzheimer's disease and its treatment-yesterday, today, and tomorrow. Kim AY, Al Jerdi S, MacDonald R, Triggle CR. Front Pharmacol 15 1399121 (2024)
- Passive Anti-Amyloid Beta Immunotherapies in Alzheimer's Disease: From Mechanisms to Therapeutic Impact. Schreiner TG, Croitoru CG, Hodorog DN, Cuciureanu DI. Biomedicines 12 1096 (2024)
- The Interplay of Protein Aggregation, Genetics, and Oxidative Stress in Alzheimer's Disease: Role for Natural Antioxidants and Immunotherapeutics. Ali J, Choe K, Park JS, Park HY, Kang H, Park TJ, Kim MO. Antioxidants (Basel) 13 862 (2024)